M

Marinomed Biotech AG
VSE:MARI

Watchlist Manager
Marinomed Biotech AG
VSE:MARI
Watchlist
Price: 18.5 EUR 1.65% Market Closed
Market Cap: 34m EUR

Relative Value

The Relative Value of one MARI stock under the Base Case scenario is 20.19 EUR. Compared to the current market price of 18.5 EUR, Marinomed Biotech AG is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MARI Relative Value
Base Case
20.19 EUR
Undervaluation 8%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
37
Median 3Y
6.9
Median 5Y
9.8
Industry
2.7
Forward
3.8
vs History
11
vs Industry
Median 3Y
-4.8
Median 5Y
-10.2
Industry
21.6
Forward
1.8
vs History
vs Industry
Median 3Y
-15.5
Median 5Y
-19.3
Industry
16.9
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-17.6
Industry
22.9
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-6.3
Industry
2.3
vs History
98
vs Industry
22
Median 3Y
8.3
Median 5Y
10.7
Industry
3
Forward
4.5
vs History
79
vs Industry
3
Median 3Y
44.2
Median 5Y
38.8
Industry
5.6
vs History
11
vs Industry
Median 3Y
-14.9
Median 5Y
-17.3
Industry
13.4
Forward
2
vs History
11
vs Industry
Median 3Y
-14.5
Median 5Y
-14.9
Industry
16.7
Forward
2.1
vs History
vs Industry
Median 3Y
-16.5
Median 5Y
-20.3
Industry
16.1
vs History
vs Industry
Median 3Y
-16.5
Median 5Y
-17.9
Industry
18.9
vs History
90
vs Industry
18
Median 3Y
7.2
Median 5Y
9
Industry
2

Multiples Across Competitors

MARI Competitors Multiples
Marinomed Biotech AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AT
Marinomed Biotech AG
VSE:MARI
32.9m EUR 2.8 6.2 2.9 2.9
US
Eli Lilly and Co
NYSE:LLY
966.6B USD 16.3 52.5 35.3 37.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
523.5B USD 5.7 20.8 17 22.1
CH
Roche Holding AG
SIX:ROG
276.2B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
220.3B GBP 5.1 31.5 109.1 159.6
CH
Novartis AG
SIX:NOVN
222.2B CHF 5 19.3 12.2 15.8
US
Merck & Co Inc
NYSE:MRK
273.4B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.7B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
AT
M
Marinomed Biotech AG
VSE:MARI
Average P/E: 22.7
6.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AT
M
Marinomed Biotech AG
VSE:MARI
Average EV/EBITDA: 400.2
2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.3
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
109.1
10%
10.9
CH
Novartis AG
SIX:NOVN
12.2
6%
2
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AT
M
Marinomed Biotech AG
VSE:MARI
Average EV/EBIT: 1 712.7
2.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.1
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.8
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5